share_log

SciSparc | CORRESP: CORRESP

SciSparc | CORRESP: CORRESP

SciSparc | CORRESP:信函
美股SEC公告 ·  03/05 12:40

Moomoo AI 已提取核心信息

SciSparc Ltd., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Tel Aviv, Israel, seeks to have the registration become effective on March 6, 2024, at 4:15 p.m. Eastern Time. This request, if granted, would allow SciSparc to proceed with its proposed public offering of securities as detailed in the Registration Statement. The company has confirmed its understanding of and commitment to its responsibilities under the Securities Act of 1933 in relation to the offering. SciSparc has requested both telephonic and written confirmation of the Registration Statement's effectiveness from the SEC.
SciSparc Ltd., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Tel Aviv, Israel, seeks to have the registration become effective on March 6, 2024, at 4:15 p.m. Eastern Time. This request, if granted, would allow SciSparc to proceed with its proposed public offering of securities as detailed in the Registration Statement. The company has confirmed its understanding of and commitment to its responsibilities under the Securities Act of 1933 in relation to the offering. SciSparc has requested both telephonic and written confirmation of the Registration Statement's effectiveness from the SEC.
生物制药公司ScisPARC Ltd. 已正式要求美国证券交易委员会(SEC)加快其F-1表格注册声明的生效。该公司总部位于以色列特拉维夫,希望注册于美国东部时间2024年3月6日下午 4:15 生效。该请求如果获得批准,将允许ScisPARC继续进行注册声明中详述的证券公开发行。该公司已确认其对1933年《证券法》规定的与本次发行有关的责任的理解和承诺。ScisPARC已要求美国证券交易委员会以电话和书面形式确认注册声明的有效性。
生物制药公司ScisPARC Ltd. 已正式要求美国证券交易委员会(SEC)加快其F-1表格注册声明的生效。该公司总部位于以色列特拉维夫,希望注册于美国东部时间2024年3月6日下午 4:15 生效。该请求如果获得批准,将允许ScisPARC继续进行注册声明中详述的证券公开发行。该公司已确认其对1933年《证券法》规定的与本次发行有关的责任的理解和承诺。ScisPARC已要求美国证券交易委员会以电话和书面形式确认注册声明的有效性。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息